Peter Pattison (@bsc_io) 's Twitter Profile
Peter Pattison

@bsc_io

President, Interventional Oncology & Embolization at Boston Scientific, Peripheral Interventions @bsc_pi

ID: 1276577559648575489

linkhttps://bit.ly/2OHGZ55 calendar_today26-06-2020 18:07:09

556 Tweet

1,1K Takipçi

567 Takip Edilen

Peter Pattison (@bsc_io) 's Twitter Profile Photo

BSC Interventional Oncology & Embolization at #SIOVegas Special thanks to Zach Berman MD, Riad Salem, Parissa Tabrizian, MD; Francis Yao, MD; Juan Gimenez, MD; Tyler Sandow, David S. Wang, MD, FSIR; Beau Bosko Toskich, MD FSIR, Diana Dinh, MD, MPH; Prof. dr. Marnix G.E.H. Lam and Venkatesh (Kavi) Krishnasamy for sharing

Peter Pattison (@bsc_io) 's Twitter Profile Photo

Thanks for a great few days at #SIOVegas, here's to more collaboration and innovation in 2025 & beyond! #irad #interventionalradiology #interventionaloncology Sphere

Peter Pattison (@bsc_io) 's Twitter Profile Photo

With 1 in 5 people around the world developing cancer in their lifetime BSC IO&E is grateful to provide our physician partners with more options to treat patients including #TheraSphere for #HCC,  freezing cancer cells to reduce pain with the Visual-ICE #cryoablation system and

With 1 in 5 people around the world developing cancer in their lifetime BSC IO&E is grateful to provide our physician partners with more options to treat patients including #TheraSphere for #HCC,  freezing cancer cells to reduce pain with the Visual-ICE #cryoablation system and
Peter Pattison (@bsc_io) 's Twitter Profile Photo

Another highlight from #SIOVegas. Excited to be a part of this important trial treating patients with painful bone metastases. #ablation #cryoablation #VisualICE #ICEfx

Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

Interview with Dr. Riad Salem Riad Salem! We talk everything IR in HCC - Y90, his Legacy trial, & I push on why no SBRT (yet) in BCLC 😃. I learned a lot. Full video in replies on YouTube. Thank you, Riad!

Peter Pattison (@bsc_io) 's Twitter Profile Photo

March is #KidneyCancerAwarenessMonth. In 2024, over 80,000 new cases of kidney cancer were diagnosed. To advance treatment options, we're excited to highlight the EuRECA study, the largest prospective, real-world multicenter study focusing on cryoablation for the treatment of

March is #KidneyCancerAwarenessMonth. In 2024, over 80,000 new cases of kidney cancer were diagnosed. To advance treatment options, we're excited to highlight the EuRECA study, the largest prospective, real-world multicenter study focusing on cryoablation for the treatment of
Peter Pattison (@bsc_io) 's Twitter Profile Photo

Preview one of SIR's Abstracts of the Year! Hear from Sam Mouli on the Frontier Study: Preliminary Results of Safety and Feasibility of Yttrium-90 TheraSphere in Recurrent Glioblastoma. Read here: irq.sirweb.org/sirtoday/2025-… #TheraSphereGBM #Y90 #FRONTIERstudy #SIR2025

Keith Pereira MD, #VIrad (@keithppereira) 's Twitter Profile Photo

IR is lighting up the city—and I’m here for it. Right in the heart of Broadway, a glowing tribute to what we do best: We stop the bleeding. We treat the cancer. We push medicine forward. Big thanks to Boston Scientific for this. #SIR25NASH #ScrubsAndStetsons #VIRad

IR is lighting up the city—and I’m here for it.

Right in the heart of Broadway, a glowing tribute to what we do best:
We stop the bleeding. 
We treat the cancer.
We push medicine forward.

Big thanks to <a href="/bostonsci/">Boston Scientific</a> for this.

#SIR25NASH #ScrubsAndStetsons #VIRad
Peter Pattison (@bsc_io) 's Twitter Profile Photo

NEW #FRONTIERstudy data presented by Sam Mouli at #SIR25NASH Learn more about Frontier here: bit.ly/3WC5TqS #RecurrentGBM #ClinicalTrial #Glioblastoma #TheraSphereGBM NorthwesternIR

Peter Pattison (@bsc_io) 's Twitter Profile Photo

Great to share more #FrontierStudy news in #BrainCancerAwarenessMonth. We are excited to be expanding the trial to treat additional patients, including treatment of recurrent GBM tumors in other areas of the brain. Learn more about the expansion of the Frontier Study highlighted